ipharmacenter Consulting services

Switzerland’s new understanding with the US goes beyond a minor tariff tweak and directly touches the country’s role as a pharma and med‑tech hub. Under a November memorandum of understanding, Washington will cap the country‑specific additional tariff on Swiss goods at 15%, bringing Switzerland into line with the EU and EFTA - while key pharmaceutical products remain largely exempt from the surcharge but under continued scrutiny.​   What the Switzerland–United States deal doe

May 16, 2024 Vyndaqel for Rare Heart Condition Now Available on the NHS Patients on the NHS suffering from a critical heart condition...

In their initial financial disclosures, the statutory health insurance providers reveal a surplus expenditure of approximately 1.9...

Keytruda (pembrolizumab) is suggested as an alternative for managing recurring or stubborn classical Hodgkin lymphoma in individuals aged...

January 08, 2024 ELFABRIO (pegunigalsidase alfa) - Unfavorable Reimbursement Opinion for Fabry Disease The reimbursement outlook for...

September 29, 2023 The German government commission urges stable financing for child and adolescent medicine, pediatric outpatient...

November 15, 2023 NICE not recommended Pluvicto for PSMA-positive hormone-relapsed metastatic prostate cancer Lutetium-177 vipivotide...

Find the latest healthcare and pharmaceutical news of France | HAS assessment outcomes and drug approvals in France of 2023

NHS to offer Tagrisso for lung cancer patients NHS England announced that it would roll out Tagrisso (osimertinib) for lung cancer...